戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  of 40 derivatives of clofilium, a class III antiarrhythmic agent.
2 and these findings support its utility as an antiarrhythmic agent.
3 factors, when patients are treated with this antiarrhythmic agent.
4 c calcium channel, and therefore a potential antiarrhythmic agent.
5 story of diabetes mellitus, and prior use of antiarrhythmic agents.
6 sis after excluding patients on pre-existing antiarrhythmic agents.
7 d susceptibility to proarrhythmic effects of antiarrhythmic agents.
8 jority of patients, necessitating the use of antiarrhythmic agents.
9 c drug development from class I to class III antiarrhythmic agents.
10 ate hERG currents and thus may act as potent antiarrhythmic agents.
11 nnel in heart, is a major target for class I antiarrhythmic agents.
12 ients) or therapy with class IC or class III antiarrhythmic agents (148 patients).
13 ee of atrial fibrillation without the use of antiarrhythmic agents; 84% were arrhythmia free when tho
14    In vitro and in vivo studies suggest that antiarrhythmic agents affect Na+ channels of cells from
15 ence of atrial arrhythmias without using any antiarrhythmic agents after the catheter ablation.
16                         Because conventional antiarrhythmic agents aiming at ion channels have proven
17 ed to investigate the cellular uptake of the antiarrhythmic agent amiodarone, a phospholipidosis-indu
18 was reported in 1 of 1 RCT (100%) of class 1 antiarrhythmic agents and 5 of 5 RCTs (100%) of warfarin
19 drugs with narrow therapeutic indexes (e.g., antiarrhythmic agents, anticoagulant agents) have demons
20                                     Numerous antiarrhythmic agents, antimicrobial drugs, psychotropic
21                            Dronedarone is an antiarrhythmic agent approved in 2009 for the treatment
22 luate the potential role of ranolazine as an antiarrhythmic agent are warranted.
23                           Although class III antiarrhythmic agents are being used increasingly for bo
24 brillation; the indications for conventional antiarrhythmic agents are decreasing because of side eff
25 lantable cardioverter defibrillators (ICDs), antiarrhythmic agents are increasingly being used as adj
26 calcium channel blockers, beta-blockers, and antiarrhythmic agents as management options.
27                                              Antiarrhythmic agents, calcium channel blockers, alcohol
28                             Amiodarone is an antiarrhythmic agent commonly used in the treatment of s
29                              Lidocaine is an antiarrhythmic agent commonly used to treat ventricular
30 incipal mechanisms of action of contemporary antiarrhythmic agents, delineates their limitations in t
31                          Celivarone is a new antiarrhythmic agent developed for the treatment of vent
32                                          The antiarrhythmic agent disopyramide and various serotonin
33  heteroaromatic derivatives of the class III antiarrhythmic agent dofetilide was synthesized and asse
34 a(2+) release events and the response to the antiarrhythmic agent flecainide in Purkinje cells and ve
35                AZD1305 is an investigational antiarrhythmic agent for management of atrial fibrillati
36               Although there are established antiarrhythmic agents for preventing and treating postop
37 miodarone loading, and 3 required additional antiarrhythmic agents for sustained cardioversion.
38  of intravenous dofetilide, a pure class III antiarrhythmic agent, for the termination of sustained a
39 ollowed by the rapid, sequential infusion of antiarrhythmic agents (i.e., adenosine, verapamil, and e
40                      The selective class III antiarrhythmic agent ibutilide prolongs action potential
41 mechanistic insights into the effects of the antiarrhythmic agents in the setting of AF-induced SND.
42            We conclude that PUFAs may act as antiarrhythmic agents in vivo in normal and Ca2+-overloa
43 replacement; (4) and absence of preoperative antiarrhythmic agent (in POD 0 model only).
44 s, range: 1 to 241 days) failed at least two antiarrhythmic agents including either flecainide or sot
45 ompared with baseline (P:<0.001), but use of antiarrhythmic agents increased marginally (P:=0.05).
46   The Vaughn Williams classification divides antiarrhythmic agents into four groups according to thei
47          The development of selective atrial antiarrhythmic agents is a current strategy for suppress
48                                  Response to antiarrhythmic agents is mixed, and cardioversion is of
49 tter in humans by ibutilide, a new class III antiarrhythmic agent, is characterized by an increase in
50                  Dofetilide, a new class III antiarrhythmic agent, is moderately effective in cardiov
51 isproportionate reporting similar to that of antiarrhythmic agents known to promote torsade de pointe
52           Our results show that the Class IB antiarrhythmic agent lidocaine blocks maintained inward
53 gest that sodium channel block with class IB antiarrhythmic agents may be effective in suppressing Td
54 ) for whom digoxin monotherapy and secondary antiarrhythmic agents (n=13) were not effective were tre
55 xamined the effect of ibutilide, a class III antiarrhythmic agent, on the energy requirement for atri
56            Rhythm control options are either antiarrhythmic agents or ablation, with each having its
57  concomitant, postcardioversion therapy with antiarrhythmic agents, patients will frequently have add
58                         Dronedarone is a new antiarrhythmic agent pharmacologically related to amioda
59                                          The antiarrhythmic agent quinidine blocks the human cardiac
60 ocytes expressing Kv1.5-GFP with the class I antiarrhythmic agent quinidine resulted in a dose- and t
61 hythmic drug therapy; and (3) intolerance to antiarrhythmic agent requiring drug cessation.
62                                The class III antiarrhythmic agent RP 58866 and its active enantiomer,
63 de fumarate is an intravenous (IV) class III antiarrhythmic agent that has been shown to be significa
64 ide fumarate is an investigational class III antiarrhythmic agent that prolongs repolarization by inc
65                         Dronedarone is a new antiarrhythmic agent that was recently approved for the
66 ntial administration of different classes of antiarrhythmic agents until conversion to sinus rhythm w
67 neous influences of direct current shock and antiarrhythmic agents, which may independently depress l
68 hibit KvLQT1, whereas clofilium, a class III antiarrhythmic agent with the propensity to induce torsa
69 hus, there is a recognized need for improved antiarrhythmic agents with actions that are selective fo
70 a that it may be possible to develop class I antiarrhythmic agents with optimized pharmacodynamic pro